Xenon Reports Positive Phase 1 and Preclinical Data for Pain Programs

Xenon reported positive Phase 1 and new preclinical data supporting advancement of XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain. XEN1701 achieved the target profile, including desired NaV1.7 receptor occupancy.